Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Investment Income (2016 - 2023)

Ironwood Pharmaceuticals' Non Operating Investment Income history spans 9 years, with the latest figure at $19000.0 for Q1 2023.

  • For Q1 2023, Non Operating Investment Income fell 97.4% year-over-year to $19000.0; the TTM value through Dec 2023 reached $19000.0, down 89.56%, while the annual FY2023 figure was $19000.0, 89.56% down from the prior year.
  • Non Operating Investment Income for Q1 2023 was $19000.0 at Ironwood Pharmaceuticals, up from -$18000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $4.5 million in Q4 2019 and bottomed at -$4.8 million in Q3 2019.
  • The 5-year median for Non Operating Investment Income is -$18000.0 (2022), against an average of -$240176.5.
  • The largest annual shift saw Non Operating Investment Income soared 199.7% in 2019 before it crashed 710.95% in 2021.
  • A 5-year view of Non Operating Investment Income shows it stood at $4.5 million in 2019, then crashed by 90.7% to $420000.0 in 2020, then plummeted by 710.95% to -$2.6 million in 2021, then surged by 99.3% to -$18000.0 in 2022, then surged by 205.56% to $19000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRWD's Non Operating Investment Income are $19000.0 (Q1 2023), -$18000.0 (Q4 2022), and $151000.0 (Q3 2022).